2m 2m 2m 2m 2m 2m 2m
STOKE THERAP (STOK)
NASDAQ
$31.11+$0.14 (+0.45%)
Price as of Jun 23, 2026 4:37 PM EDT- $1.9BMarket Cap
- 167.21%1-Year Change
- BiotechnologyIndustry
STOKE THERAP (STOK)
$31.11+$0.14 (+0.45%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 184.4M +404.50% | 36.6M +316.34% | 8.8M -29.22% | 12.4M N/A | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 184.4M +404.50% | 36.6M +316.34% | 8.8M -29.22% | 12.4M N/A | |
Sales and Marketing Expense | 67.1M N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -137.9M +54.74% | -89.1M +8.39% | -82.2M +5.65% | -77.8M +43.70% | |
Depreciation and Amortization Expense | 1.8M -18.70% | 2.2M -11.83% | 2.5M +59.70% | 1.5M +58.73% | |
Total Operating Expenses | 205.0M +48.64% | 137.9M +11.63% | 123.6M +5.82% | 116.8M +35.67% | |
Operating Profit | -20.6M -79.69% | -101.4M -11.68% | -114.8M +9.98% | -104.4M +21.25% | |
Interest Income | 13.8M +8.69% | 12.7M N/A | N/A N/A | N/A N/A | |
Interest Expense | -9,000 -65.38% | -26,000 N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 13.8M +8.85% | 12.6M N/A | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | 13.7M +10.60% | 12.4M +23.00% | 10.1M +206.29% | 3.3M +1,165.00% | |
Income before Taxes | -20.6M -79.69% | -101.4M -11.68% | -114.8M +9.98% | -104.4M +21.25% | |
Income Taxes | 0 N/A | N/A N/A | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -6.9M -92.26% | -89.0M -15.01% | -104.7M +3.59% | -101.1M +17.79% | |
Net Income from Continuing Operations Applicable to Common | -6.9M -92.26% | -89.0M -15.01% | -104.7M +3.59% | -101.1M +17.79% | |
Basic EPS and Net Income | -0.12 -92.73% | -1.65 -30.67% | -2.38 -8.46% | -2.60 +11.11% | |
Diluted EPS and Net Income | -0.12 -92.73% | -1.65 -30.67% | -2.38 -8.46% | -2.60 +11.11% | |
Basic Weighted Average Shares | 59.2M +9.65% | 54.0M +22.76% | 44.0M +13.10% | 38.9M +5.87% | |
Diluted Weighted Average Shares | 59.2M +9.65% | 54.0M +22.76% | 44.0M +13.10% | 38.9M +5.87% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 84.2M -34.19% | 128.0M -33.15% | 191.4M +68.59% | 113.6M -21.63% | |
Short-Term Investments | 200.4M +125.44% | 88.9M +793.45% | 10.0M -91.42% | 116.0M +54.89% | |
Cash and Cash Equivalents and Short-Term Investments | 284.7M +31.25% | 216.9M +7.70% | 201.4M -12.28% | 229.6M +4.45% | |
Total Current Assets | 305.7M +31.34% | 232.8M +8.09% | 215.3M -11.77% | 244.1M +6.48% | |
Accumulated Depreciation | 10.1M +14.67% | 8.8M +32.63% | 6.7M +58.57% | 4.2M +58.10% | |
Property and Plant and Equipment and Net | 3.1M -19.52% | 3.9M -32.87% | 5.8M -12.76% | 6.7M +61.27% | |
Total Long-Term Assets | 3.1M -19.52% | 3.9M -32.87% | 5.8M -12.76% | 6.7M +61.27% | |
Total Assets | 418.4M +54.09% | 271.6M +18.92% | 228.3M -10.83% | 256.1M +7.20% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 57.9M +44.49% | 40.1M +29.97% | 30.8M -1.83% | 31.4M +83.17% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 8.1M +226.96% | 2.5M -93.47% | 38.0M -4.69% | 39.8M +908.46% | |
Total Liabilities | 66.0M +55.12% | 42.5M -38.16% | 68.8M -3.43% | 71.2M +237.72% | |
Retained Earnings | -497.7M +1.40% | -490.8M +22.14% | -401.8M +35.23% | -297.1M +51.54% | |
Total Stockholders Equity | 352.5M +53.90% | 229.0M +43.53% | 159.6M -13.68% | 184.8M -15.12% | |
Total Shares Outstanding | 58.9M +9.05% | 54.0M +17.67% | 45.9M +16.43% | 39.4M +6.88% | |
Cash Flow | |||||
Cash from Operating Activities | 45.6M +152.49% | -86.9M +7.13% | -81.1M +154.40% | -31.9M -52.37% | |
Capital Expenditures | 670,000 +230.05% | 203,000 -87.44% | 1.6M -59.21% | 4.0M +230.17% | |
Cash from Investing Activities | -186.8M +73.82% | -107.5M -201.44% | 105.9M +330.91% | -45.9M -39.97% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 97.4M -25.71% | 131.1M +147.31% | 53.0M +14.22% | 46.4M +3,514.41% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -11.16% -95.97% | -277.31% -78.79% | -1,307.21% +55.39% | -841.24% N/A | |
Return on Assets | -2.00% -94.39% | -35.60% -17.65% | -43.23% +5.84% | -40.84% +27.75% | |
Return on Equity | -2.37% -94.83% | -45.80% -24.67% | -60.80% +21.10% | -50.20% +47.40% | |
Revenue Growth | 404.50% +27.87% | 316.34% +1,182.55% | -29.22% N/A | N/A N/A | |
Current Ratio | 5.28 -9.10% | 5.81 -16.84% | 6.99 -10.13% | 7.77 -41.87% | |
Cash Ratio | 1.46 -54.46% | 3.20 -48.56% | 6.21 +71.73% | 3.62 -57.21% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow